Home
About
Overview
Sharing Data
ORCID
Help
History (15)
Pain assessment using the NIH Toolbox.
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Principal Investigator
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.
NF-?B, Mesenchymal Differentiation and Glioblastoma.
See All 15 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Navari, Rudolph
One or more keywords matched the following items that are connected to
Navari, Rudolph
Item Type
Name
Academic Article
Safety of Polysorbate 80 in the Oncology Setting.
Academic Article
Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.
Concept
Administration, Intravenous
Search Criteria
Administration Intravenous